TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results, Beats Estimates By $2.19 EPS

TG Therapeutics (NASDAQ:TGTX) announced its quarterly earnings data on Monday. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $2.19, Zacks reports. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company had revenue of $161.71 million for the quarter, compared to analysts’ expectations of $152.12 million. During the same quarter in the prior year, the firm earned $0.02 earnings per share. TG Therapeutics’s revenue was up 92.7% compared to the same quarter last year. TG Therapeutics updated its FY 2025 guidance to EPS.

TG Therapeutics Stock Performance

Shares of TGTX opened at $34.78 on Monday. TG Therapeutics has a 12 month low of $22.92 and a 12 month high of $46.48. The stock has a fifty day moving average price of $33.45 and a 200-day moving average price of $34.81. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. The firm has a market cap of $5.52 billion, a PE ratio of 94.00 and a beta of 1.97.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director owned 94,061 shares in the company, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.64% of the company’s stock.

Institutional Trading of TG Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp lifted its holdings in shares of TG Therapeutics by 2.5% during the 2nd quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company’s stock valued at $274,180,000 after purchasing an additional 184,339 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after acquiring an additional 345,059 shares during the last quarter. Public Sector Pension Investment Board raised its stake in TG Therapeutics by 9.2% in the 2nd quarter. Public Sector Pension Investment Board now owns 462,360 shares of the biopharmaceutical company’s stock worth $16,640,000 after acquiring an additional 39,042 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in TG Therapeutics by 5.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock worth $11,319,000 after acquiring an additional 14,689 shares during the last quarter. Finally, Rafferty Asset Management LLC raised its stake in TG Therapeutics by 3.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 188,220 shares of the biopharmaceutical company’s stock worth $6,774,000 after acquiring an additional 6,359 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 price objective on the stock in a research note on Thursday, July 10th. HC Wainwright began coverage on TG Therapeutics in a research report on Monday, October 6th. They set a “buy” rating and a $60.00 target price on the stock. Finally, B. Riley increased their target price on TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.75.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.